Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Biogen

A Colorado panel of medical and pharmacy experts will decide whose medicine to make affordable this summer

Starting this summer, Colorado's Prescription Drug Affordability Board will choose up to 18 high-cost drugs for review.

Fortune

Drug for rare form of Lou Gehrig’s disease OK'd by FDA

U.S. health regulators have approved a first-of-a-kind drug for a rare form of Lou Gehrig’s disease

The Independent UK

The VA will pay for some to get new Alzheimer’s drug

The U.S. Veterans Health Administration will pay for some beneficiaries to get a new Alzheimer’s disease drug from Eisai Co. and Biogen Inc., positive news for a treatment that Eisai expects to bring in billions of dollar in sales in the next few years.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

Commentary: We shouldn’t get caught up in the hype over new Alzheimer’s drug

This month, the Food and Drug Administration approved a new drug, lecanemab, for the treatment of Alzheimer’s disease. The drug, sold under the brand name Leqembi, was developed by Japanese pharmaceutical company Eisai and will be marketed commercially in partnership with American pharmaceutical company Biogen. Biogen, notably, is the maker…

Chicago Tribune

Commentary: Too soon to celebrate new Alzheimer’s drug

A treatment that improves Alzheimer’s disease would be a great advance, but Leqembi (lecanemab), which recently received accelerated approval from the FDA, is not that drug. Yes, lecanemab slows decline to an extent detectable on a test, but not to an extent that a relative or caretaker would notice. This…

Tribune News Service

What the FDA's accelerated approval of a new Alzheimer's drug could mean for those with the disease – 5 questions answered about lecanemab

The U.S. Food and Drug Administration approved the medication lecanemab, sold under the brand name Leqembi, on Jan. 6, 2023, through an “accelerated approval pathway” that fast-tracks promising clinical treatments for diseases in which there are no other currently effective options.

The Conversation

US Approves New Drug to Treat Alzheimer's Disease

The US Food and Drug Administration on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer's disease. The FDA approval of the drug, Leqembi, also known as lecanemab, comes just days after the regulatory agency was harshly criticized…

Asharq Al-Awsat

Read news from The Economist, FT, and more,
with one subscription

Alzheimer’s drug that slows disease progression approved by FDA

U.S. health officials have approved a new Alzheimer’s drug that modestly slows the brain-robbing disease

The Independent UK

FDA grants fast-track approval to experimental Alzheimer's drug

The FDA approved lecanemab, which has shown to slow the progression of Alzheimer's disease.

Axios

Alzheimer's drug that modestly slows disease OK'd by FDA

U.S. health officials have approved a new Alzheimer’s drug that modestly slows the brain-robbing disease

The Independent UK

2023 could be a banner year for prescription drugs

There's a large pipeline of promising yet expensive drugs that could get approved.

Axios

FDA’s approval of Biogen Alzheimer’s drug slammed in report

U.S. health officials’ approval process for Biogen Inc.’s controversial Alzheimer’s drug was “rife with irregularities,” raising serious concerns about protocol lapses at the agency, congressional investigators said.

Tribune News Service

Probe: Alzheimer's drug approval 'rife with irregularities'

The Food and Drug Administration's contentious approval of a questionable Alzheimer's drug is taking another hit

The Independent UK

House report questions FDA’s approval of Alzheimer’s drug

WASHINGTON — A joint investigation released Thursday by House Democrats identified unusual collaboration between Food and Drug Administration officials and drugmaker Biogen, highlighting potential problems in the agency’s approval of the controversial Alzheimer’s drug Aduhelm.

Tribune News Service

Get all your
news in one place.

100's of premium titles.
One news app.

Roll Call

House report questions FDA's approval of Alzheimer's drug - Roll Call

House Democrats releases a report highlighting potential problems in the FDA's approval of Alzheimer's drug Aduhelm.

The Conversation

Lecanemab: Experimental drug is a ray of hope for Alzheimer's disease

On Nov. 30, Eisai and Biogen announced the results of their latest phase 3 clinical trial in Alzheimer’s disease. The verdict: an 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The study…

The New Daily

Lots of breakthroughs, still no cure. Do new dementia drugs bring us any closer?

We often hear about dementia breakthroughs in the news – new genes being discovered, new blood tests being developed, new drugs being tested.

The Conversation

Lots of 'breakthroughs', still no cure. Do the new dementia drugs bring us any closer?

We often hear about “dementia breakthroughs” in the news – new genes being discovered, new blood tests being developed, new drugs being tested.

Get all your
news in one place.

100's of premium titles.
One news app.

Tribune News Service

Lisa Jarvis: That blockbuster Alzheimer’s drug? It’s not a cure

Biogen Inc. and Eisai Co. caused a stir in September when they announced positive results in a late-stage trial for a closely watched Alzheimer’s drug, lecanemab. Doctors tempered their excitement, though, until they could scrutinize the full peer-reviewed data.

Al Jazeera

Data shows drug slowing Alzheimer’s but doubts over effect remain

Lecanemab modestly slows disease’s inevitable worsening, but it remains unclear how much of a difference it will make.

The New Daily

‘Momentous breakthrough’: New Alzheimer’s drug lives up to bold claims, with caveats

Data supports claims that a new drug reduced cognitive and functional decline in Alzheimer's patients by 27 per cent in a clinical trial.

WEKU

Study: Alzheimer's drug shows modest success slowing declines in memory, thinking

In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.

Tribune News Service

Alzheimer's drug sparks hot debate over benefits as risks like brain bleeding emerge

Eisai Co. unveiled much-anticipated findings on its experimental Alzheimer’s drug, providing tinder for the hot debate over whether its modest efficacy is worth potential risks that include serious brain bleeding.

The Independent UK

Drug slows Alzheimer's but can it make a real difference?

New data shows an experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening

Axios

Safety concerns hang over new Alzheimer's treatment

Two deaths linked to the drug may present a more complicated path to approval.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

National Institutes of Health

80 stories

STAT

33 stories

New England Journal of Medicine

31 stories

Alzheimer Association

19 stories

Leqembi

18 stories

National Institute on Aging

12 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.